Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lumos Pharma Q3 EPS $(1.04) Beats $(1.15) Estimate, Sales $7.00K Miss $320.00K Estimate

Author: Benzinga Newsdesk | November 07, 2023 06:05pm
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.04) per share which beat the analyst consensus estimate of $(1.15) by 9.57 percent. This is a 20.93 percent decrease over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $7.00 thousand which missed the analyst consensus estimate of $320.00 thousand by 97.81 percent. This is a 98.59 percent decrease over sales of $497.00 thousand the same period last year.

Posted In: LUMO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist